Drug General Information
Drug ID	D05NDR
Former ID	DCL000640
Drug Name	Sifalimumab
Drug Type	Antibody
Indication	Advanced renal cell carcinoma [ICD9: 189; ICD10:C64]		Approved	[529282], [543015]
	Systemic lupus erythematosus; Myositis [ICD9: 695, 710.0, 729.1; ICD10:L51-L54, M32, M60]		Phase 2	[543015], [551134]
Company	AstraZeneca; MedImmune
Structure		Download 2D MOL 3D MOL
Formula	C56H87NO16
PubChem Compound ID	23724530
Target and Pathway
Target(s)	Interferon-alpha/beta receptor	Target Info		[550288], [551134]
KEGG Pathway	Cytokine-cytokine receptor interaction
	PI3K-Akt signaling pathway
	Osteoclast differentiation
	Toll-like receptor signaling pathway
	Jak-STAT signaling pathway
	Natural killer cell mediated cytotoxicity
	Hepatitis C
	Hepatitis B
	Measles
	Influenza A
	Herpes simplex infection
Reactome	Interferon alpha/beta signaling
	Regulation of IFNA signaling
WikiPathways	Toll-like receptor signaling pathway
	Interferon type I signaling pathways
	Interferon alpha/beta signaling
	Regulation of toll-like receptor signaling pathway
	Osteoclast Signaling
References
Ref 529282	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
Ref 543015	(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8257).
Ref 551134	Clinical pipeline report, company report or official report of MedImmune (2011).
Ref 550288	Clinical pipeline report, company report or official report of AstraZeneca (2009).
Ref 551134	Clinical pipeline report, company report or official report of MedImmune (2011).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.